Photodynamic therapy for choroidal neovascularization in pediatric patients

被引:30
作者
Giansanti, F
Virgili, G
Varano, M
Tedeschi, M
Rapizzi, E
Giacomelli, G
Menchini, U
机构
[1] Univ Florence, Eye Clin, Dept Otoneuroophthalmol Surg Sci, I-50134 Florence, Italy
[2] GB Bietti Eye Fdn, Rome, Italy
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2005年 / 25卷 / 05期
关键词
children; choroidal neovascularization; photodynamic therapy; verteporfin;
D O I
10.1097/00006982-200507000-00009
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report the use of photodynamic therapy (PDT) for choroidal neovascularization (CNV) in pediatric patients. Methods: Five patients (age range, 7-15 years) who underwent PDT for idiopathic CNV (n = 2) or CNV secondary to macular toxoplasmic scar (n = 3) were included in this study. Follow-up ranged from 12 months to 18 months. PDT was performed according to the standard protocol. We evaluated visual acuity, fluorescein leakage from the CNV, greatest linear dimension of the lesion, and occurrence of ocular or systemic adverse events at baseline and during follow-up. Results: No severe or moderate visual loss occurred in all cases during follow-up. PDT reduced CNV leakage in four cases. No serious ocular or systemic adverse events were recorded. Retinal pigment epithelium atrophic changes were observed around the regressed CNV, but they did not appear to cause visual loss. Conclusions: PDT was safe for pediatric patients, and visual acuity was substantially stable after one or few treatments. Further follow-up is needed to assess if retinal pigment epithelium atrophic changes around the regressed CNV, possibly related to PDT, could affect vision in the long term.
引用
收藏
页码:590 / 596
页数:7
相关论文
共 9 条
[1]   Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia - 2-year results of a randomized clinical Trial - VIP report no. 3 [J].
Blinder, KJ ;
Blumenkranz, MS ;
Bressler, NM ;
Bressler, SB ;
Donati, G ;
Lewis, H ;
Lim, JI ;
Menchini, U ;
Miller, JW ;
Mones, JM ;
Potter, MJ ;
Pournaras, C ;
Reaves, A ;
Rosenfeld, P ;
Schachat, AP ;
Schmidt-Erfurth, U ;
Sickenberg, M ;
Singerman, LJ ;
Slakter, J ;
Strong, HA ;
Virgili, G ;
Williams, GA .
OPHTHALMOLOGY, 2003, 110 (04) :667-673
[2]  
Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
[3]  
HAMOVICI R, 1997, CURR EYE RES, V16, P83
[4]  
Husain D., 1996, Investigative Ophthalmology and Visual Science, V37, pS223
[5]   Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children [J].
Mimouni, KF ;
Bressler, SB ;
Bressler, NM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (06) :900-902
[6]   Lipid metabolism in retinal pigment epithelium (RPE): a possible role of LDL receptors [J].
Noske, UM ;
Schmidt-Erfurth, U ;
Meyer, C ;
Diddens, H .
OPHTHALMOLOGE, 1998, 95 (12) :814-819
[7]   Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey [J].
Reinke, MH ;
Canakis, C ;
Husain, D ;
Michaud, N ;
Flotte, TJ ;
Gragoudas, ES ;
Miller, JW .
OPHTHALMOLOGY, 1999, 106 (10) :1915-1923
[8]   A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes [J].
Sickenberg, M ;
Schmidt-Erfurth, U ;
Miller, JW ;
Pournaras, CJ ;
Zografos, L ;
Piguet, B ;
Donati, G ;
Laqua, H ;
Barbazetto, I ;
Gragoudas, ES ;
Lane, AM ;
Birngruber, R ;
van den Bergh, H ;
Strong, HA ;
Manjuris, U ;
Gray, T ;
Fsadni, M ;
Bressler, NM .
ARCHIVES OF OPHTHALMOLOGY, 2000, 118 (03) :327-336
[9]  
*TAP STUD GROUP PR, 2002, RETINA, V22, P6